Equillium Stock

Equillium EBITDA per Employee

The EBITDA per Employee of Equillium (EQ) as of Aug 9, 2026 is -1.07 M USD. In the previous year, EBITDA per Employee was -375,863.64 USD — a change of 185.81% (lower).

EBITDA per Employee

-1.07 MUSD

YoY

185.81%

Last updated:

EBITDA per Employee of Equillium is 2026 -1.07 M USD. EBITDA per Employee of Equillium was 2025 -375,863.64 USD. It decreases by 185.81% lower compared to the previous year.
Access this data via the Eulerpool API

Equillium Stock analysis

What does Equillium do? Equillium Inc is an emerging biotechnology company specializing in the research and development of therapies for the treatment of inflammatory and autoimmune diseases. The company was founded in 2017 by a group of experienced biotech entrepreneurs who aim to develop innovative and effective treatment methods to improve patients' quality of life. Equillium's business model focuses on the discovery and development of new therapies based on the modulation of the CD6 signaling pathway, a central regulator of the immune system. Equillium's technology aims to modulate the immune system to suppress an inflammatory response associated with autoimmune and other inflammatory diseases. The company collaborates closely with leading university research laboratories and experts in the field to develop effective therapies. Equillium targets a wide range of disease areas, including autoimmune diseases such as lupus, psoriasis, and Crohn's disease. The company has also developed a program to treat COVID-19, aiming to reduce the immune-mediated inflammatory response associated with severe cases of COVID-19. Equillium's product portfolio includes EQ001, a monoclonal antibody used for the treatment of lupus and other autoimmune diseases. EQ001 blocks the CD6 signaling pathway, thereby reducing inflammatory responses that attack healthy tissues in the body. The company is also working on developing a novel platform technology to explore additional therapy options based on the CD6 signaling pathway. Equillium has a strong funding base and is supported by some of the most renowned biotech investors. The company has a comprehensive pipeline of potential therapies that are intended to address a variety of indications in the future. Overall, Equillium's advanced biotechnological research and development have contributed to the discovery of new and effective ways to treat inflammatory and autoimmune diseases. The company is well-positioned to expand in this area of medicine and improve therapy options for patients worldwide. Equillium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Equillium stock

EBITDA per Employee of Equillium is -1.07 M USD in 2026.

EBITDA per Employee of Equillium changed from -375,863.64 USD to -1.07 M USD, representing a 185.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Equillium since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Equillium historically and in real time.

Access this data via the Eulerpool API

Workforce — Equillium

All Key Metrics — Equillium